In this video, Badar M. Mian, MD, FACS, discusses the key points of his presentation, “Clinical trials of TP biopsy,’ which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Mian is a professor of surgery and urology at Albany Med Urology in Albany, New York.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.